THE TAPE
BMY · Pharmaceutical Preparations · $128.6B

Bristol-Myers Squibb Co.

$62.93▼ −0.79%
Last close
Relative strength
62RS
of 99, against every stock▼ -3 on the month
Cooling off
Turning
−1.1%
six months against Pharmaceutical Preparations
52-week range
−8.3%
from the high
$45.27$68.64
Setup
On no screen
No base, flag or squeeze in place tonight. What is and is not there
No report date on the calendar.
Growth FLATProof SHOWN
Quarter to Sep 30, revenue +7% on a year ago
Why it is on no screen

BMY is off the screens on one check: relative strength.

A base has formed12.6 weeks, from 56.15 to 68.64.
Long enough to count12.6 weeks against 3 needed.
Shallow enough18.2% deep against 35% allowed.
Close to its pivot-8.3% from the pivot; listed down to -20%.
Relative strengthRS 62 against 70 needed.

Measured against the base-and-breakout thresholds. The other screens use their own numbers, so a name can miss here and still be a fair-looking chart.

Draw
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year
Support and resistance
Support below
$61.92
-1.6% · tested 5× · last 4 sessions ago
Resistance above
$63.59
+1.0% · tested 5× · last 11 sessions ago

Prices this stock has turned at three or more times in the last 120 sessions, with how many times. Where buyers and sellers showed up before, not a forecast, an entry or a stop.

The read

Bristol-Myers Squibb Co. is not on any of the screens right now. Its relative strength rating is 62, and it sits in Pharmaceutical Preparations.

Against its industry
TurningBehind its industry over six months, but ahead over one and three.
One month against its industry
+0.8%
Three months against its industry
+10.1%
Six months against its industry
-1.1%

Read against an equal-weighted index of Pharmaceutical Preparations, which is +10.9% against the S&P 500 over six months Partly aligned.

Peers
Catalyst roadmap

Nothing dated in the next three months that we can ingest automatically.

How it moves on earnings

On average 4.2% either way across its last 8 reports.

Checking your subscription…

Close before the report day to close after it, so it holds whether the company reported before the open or after the close.

The business
Revenue
$50.0B
+6.9% year on year
Operating margin
—
Net margin
18.5%
Free cash flow
$9.3B
7.2% of market cap
Price to sales
2.57×
Price to earnings
13.9×

Twelve months to Sep 30, 2026, the four latest quarters in the company’s SEC filings, with the fiscal fourth quarter worked out from the annual report. Revenue growth is the latest quarter against the same quarter a year earlier.

The latest quarter, read by fixed rules · reported Oct 29
Key takeaway
Profitable and cash generating; the question is growth.
Revenue
$13.1B
+0.7% QoQ · +6.9% YoY
Gross margin
—
Net income
$2.2B
Positive
Free cash flow
$3.8B
Cash generating

What the numbers say

  • Revenue +6.9% year over year, +0.7% on the quarter
  • Good: Profitable: net income $2.16B
  • Good: Cash generating: operating cash flow $4.18B, free cash flow $3.84B
  • Weak: Net debt $33.04B · cash $9.57B
Revenue by quarter
Free cash flow
Net income
shares +0.7% in a year · net debt $33.0B
Final read
Growth: FLAT · Economic proof: SHOWN
Key question: Can the cash generation hold as growth slows?
The next test is the balance sheet: net debt $33.04B · cash $9.57B.

From the company’s 10-Q and 10-K filings, by Market Desk’s rules. Every line, the takeaway and the final read are fixed rules on the filed numbers; nothing reads the press release, and none of it enters a screen or a rating. Every recent reporter.

Tracked funds

Held by 1 of 46 tracked funds at the end of Q3 2026.

Last quarter: 1 added.

Checking your subscription…

From 13F filings, which show long stock only and arrive up to 45 days after the quarter. The broad quant funds are left out.

Flagged by the market sweep
Reported resultsFiling · 2026-10-30
2.02
No measurable effect: stocks behave like random ones over the next three sessions (2,340 cases over 54 nights).
Earnings comingEvent · 2026-10-28
reports 2026-10-29 bmo
No measurable effect: stocks behave like random ones over the next three sessions (2,970 cases over 40 nights).
Unusual volumeTape · 2026-09-19
12.9 sigma
After this signal, stocks have lagged random stocks by 0.1% over the next three sessions (6,474 cases over 55 nights). Against their own sector they have lagged by 0.4%.

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means. The track record is the sweep's own, measured against random stocks over the last 90 days.

In the news
Insiders
Bought on the open market
0
Sold on the open market
2
$437,248 total

Sold: Massacesi Cristian, Holzer Phil M.

Not counted above: 19 filings for awards, option exercises, gifts or shares withheld to pay tax. Those follow a vesting schedule nobody chose the timing of, and counting them as selling is how that number gets misread.

Most recent filings
2026-11-03 Lenkowsky Adam · EVP, Chief Commercial Officeroption exercise7,522
2026-11-03 Lenkowsky Adam · EVP, Chief Commercial Officerwithheld for tax3,848$237,460
2026-11-01 BOERNER CHRISTOPHER S. · Chief Executive Officer, Directoroption exercise2,964
2026-11-01 BOERNER CHRISTOPHER S. · Chief Executive Officer, Directorwithheld for tax1,724$107,716
2026-11-01 Shanahan Karin · EVP, Chief Supply Chain & Opsoption exercise6,281
2026-11-01 Shanahan Karin · EVP, Chief Supply Chain & Opswithheld for tax3,213$200,748
2026-11-01 Meyers Gregory Scott · EVP, Chief Digital & Tech Off.option exercise6,281
2026-11-01 Meyers Gregory Scott · EVP, Chief Digital & Tech Off.withheld for tax2,665$166,509

From SEC Form 4, filed within two business days of the trade. What was filed, not what it means.

What analysts expect
Strong buy4
Buy6
Hold17
Sell1
Strong sell0

These are analysts’ estimates, not ours, and not a projection this site endorses. They are published here because what the sell side expects is itself a fact about the market.

Checking your subscription…

Gamma concentration

No option open interest for this company. Most listed names have no options at all, and we only read chains for names carrying a dated event, so this is a normal reading rather than a fault.

X-ray

No completed base to compare this one with yet.

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. A stock on a screen matches a shape; that is not a prediction. Prices are end-of-day, not live.

What that means, in full
Bristol-Myers Squibb Co. (BMY) — The Tape